Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology

Abstract

Hepatitis B infection (HBV) is one of the most common causes of hepatocellular carcinoma (HCC) worldwide. The age of occurrence, prognosis and incidence vary dramatically depending on the region of the world. This geographic variation is largely dependent on the contrasting incidence of HBV, age of transmission of the virus, the timing of integration into the human genome, and different HBV genotypes, as well as environmental factors. It results in a wide difference in viral interaction with the immune system, genomic modulation and the consequent development of HCC in an individual. In this review, we describe many factors implicated in HCC development, provide insight regarding at-risk populations and explain societal recommendations for HCC surveillance in persons living with HBV in different continents of the world.

Keywords

HCC / HBV / continent / risk

References

[1] Ferlay J,Bray F,Mathers C.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer2010;127:2893-917

[2] Mittal S.Epidemiology of hepatocellular carcinoma: consider the population.J Clin Gastroenterol2013;47:S2-6 PMCID:PMC3683119

[3] Altekruse SF,Reichman ME.Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J Clin Oncol2009;27:1485-91 PMCID:PMC2668555

[4] Kew MC.Hepatocellular carcinoma: epidemiology and risk factors.J Hepatocell Carcinoma2014;1:115-25 PMCID:PMC4918271

[5] Bréchot C.Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms.Gastroenterology2004;127:S56-61

[6] Chen CJ,Su J.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA2006;295:65-73

[7] Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.Lancet Gastroenterol Hepatol2018;3:383-403

[8] Lim JK,Kim WR,Perumalswami P.Prevalence of Chronic Hepatitis B Virus Infection in the United States.Am J Gastroenterol2020;115:1429-38

[9] Fattovich G,Donato F.Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.J Hepatol2008;48:335-52

[10] El-Serag HB.Epidemiology of viral hepatitis and hepatocellular carcinoma.Gastroenterology2012;142:1264-73.e1 PMCID:PMC3338949

[11] Kuper H,Kaklamani E.Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma.Int J Cancer2000;85:498-502

[12] El-Serag HB.Epidemiology of hepatocellular carcinoma in the United States: where are we?.Hepatology2014;60:1767-75 PMCID:PMC4211957

[13] Coffin CS,Ma MM.Canadian Association for the Study of the LiverManagement of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.Can J Gastroenterol2012;26:917-38 PMCID:PMC3551569

[14] Ashhab AA,Powell J.Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA.Eur J Gastroenterol Hepatol2019;31:24-28

[15] Ashhab AA,Powell J.Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant.J Hepatol2017;67:648-9

[16] Ching LK,Bulkow L.Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people.Liver Int2016;36:1507-15 PMCID:PMC5021564

[17] Hayashi S,Simons BC.An association between core mutations in hepatitis B virus genotype F1b and hepatocellular carcinoma in Alaskan native people.Hepatology2019;69:19-33

[18] Kallwitz ER,Allison MA.Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage.Clin Gastroenterol Hepatol2015;13:569-76 PMCID:PMC4333050

[19] Méndez-Sánchez N,Reyes A.Etiology of liver cirrhosis in Mexico.Ann Hepatol2004;3:30-3

[20] Arab JP,Álvares-da-Silva MR.Latin American Association for the Study of the Liver (ALEH) Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease.Ann Hepatol2020;19:674-90

[21] Lizardi-Cervera J,Chávez-Tapia NC,Esquivel MU.Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects.Rev Gastroenterol Mex2006;71:453-9

[22] Goldberg DS,Serper M.Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.Hepatology2017;65:864-74

[23] Papatheodoridis G,Sypsa V.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol2016;64:800-6

[24] Sharma SA,Hansen BE.Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.J Hepatol2017;S0168-8278(17)32248

[25] Lin OS,Sanders GD.Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.Aliment Pharmacol Ther2004;19:1159-72

[26] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology2018;68:723-50

[27] Singal AG,Pillai A.Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.PLoS Med2014;11:e1001624 PMCID:PMC3972088

[28] World Health Organization. Global Cancer Observatory. Available from: https://gco.iarc.fr/. [Last accessed on 17 Mar 2021]

[29] Fassio E,Santa C.Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study.Ann Hepatol2010;9:63-9

[30] Carrilho FJ,Branco F,Mattos AA.Brazilian HCC Study GroupClinical and epidemiological aspects of hepatocellular carcinoma in Brazil.Clinics (Sao Paulo)2010;65:1285-90 PMCID:PMC3020338

[31] Debes JD,Chan AJ.Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy.Liver Int2018;38:136-43

[32] Chan AJ,Kikuchi L.Early Age Hepatocellular Carcinoma Associated With Hepatitis B Infection in South America.Clin Gastroenterol Hepatol2017;15:1631-2

[33] Marchio A,Ruiz E.Early-onset liver cancer in South America associates with low hepatitis B virus DNA burden.Sci Rep2018;8:12031 PMCID:PMC6089985

[34] Wong DK,Cheng SCY.Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis.Clin Gastroenterol Hepatol2020;18:449-46

[35] Mattos Â,Debes JD.Hepatocellular carcinoma: Unraveling the role of occult hepatitis B virus infection.Clin Gastroenterol Hepatol2021;19:407-8 PMCID:PMC7501160

[36] Branco F,Coral GP.Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil.Arq Gastroenterol2007;44:58-63

[37] Livingston SE,McMahon BJ.Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F.J Infect Dis2007;195:5-11

[38] Silva Souza ACD,Kretzmann-Filho NA.Identification of hepatitis B virus A1762T/G1764A double mutant strain in patients in Southern Brazil.Braz J Infect Dis2017;21:525-9

[39] Wranke A,Parana R.Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).Liver Int2018;38:842-50

[40] Marcon PDS,Kliemann DA,de Mattos AA.Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study.World J Gastroenterol2018;24:613-22 PMCID:PMC5799862

[41] Ramírez-Soto MC,Cabezas C.Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: An analysis of death certificate data. Vaccine 2017;35:3808-12.

[42] Appel-da-Silva MC,Dossin IA,Branco F.Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study.World J Gastroenterol2016;22:10219-25 PMCID:PMC5155181

[43] Piñero F,Marciano S.Surveillance for hepatocellular carcinoma: Does the place where ultrasound is performed impact its effectiveness?.Dig Dis Sci2019;64:718-28

[44] Alvarado-Mora MV.Epidemiological update of hepatitis B, C and delta in Latin America.Antivir Ther2013;18:429-33

[45] Méndez-Sánchez N,Alves de Mattos A.Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma.Ann Hepatol2014;13 Suppl 1:S4-40

[46] Ferraz ML,Perez RM.Brazilian Society of Hepatology and Brazilian Society of Infectious Diseases Guidelines for the Diagnosis and Treatment of Hepatitis B.Braz J Infect Dis2020;24:434-51

[47] Piñero F,Aballay Soteras G.Argentinean Association for the Study of Liver Diseases (AA.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma.Ann Hepatol2020;19:546-69

[48] Tzartzeva K,Rich NE.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis.Gastroenterology2018;154:1706-18.e1 PMCID:PMC5927818

[49] Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[50] Akinyemiju T,Abera S et al.Global Burden of Disease Liver Cancer CollaborationThe burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015.JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[51] Lai A,Presti AL.What is changed in HBV molecular epidemiology in Italy?.J Med Virol2018;90:786-95

[52] Goutté N,Bendersky N,Falissard B.Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country.J Hepatol2017;66:537-44

[53] Allaire M,Brichler S.Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West.Clin Res Hepatol Gastroenterol2020;45:101436

[54] Coppola N,Pisaturo M.Hepatitis B virus infection in immigrant populations.World J Hepatol2015;7:2955-61 PMCID:PMC4691698

[55] in cancer control. Innovations and research. Proceedings of the sixth annual meeting. A combined meeting of the Association of Community Cancer Centers/Association of American Cancer Institutes. Washington, D.C., March 15-16, 1988.Prog Clin Biol Res1989;293:1-407

[56] Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol2017;67:370-98

[57] Papatheodoridis GV,Dalekos GN.The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.Hepatology2017;66:1444-53

[58] Su TH,Chen CY.C-TEAM study group and the Taiwan Liver Diseases ConsortiumFour-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.Liver Int2016;36:1755-64

[59] Sánchez-Tapias JM,Mas A,Rodés J.Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.Gastroenterology2002;123:1848-56

[60] Chen CJ,Iloeje UH.REVEAL-HBV Study GroupHepatitis B virus DNA levels and outcomes in chronic hepatitis B.Hepatology2009;49:S72-84

[61] Yang HI,Chan HL.Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.Lancet Oncol2011;12:568-74

[62] Yang HI,Liaw YF.Hepatitis B e antigen and the risk of hepatocellular carcinoma.N Engl J Med2002;347:168-74

[63] Loomba R,Yang HI.Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma.Clin Gastroenterol Hepatol2013;11:1636-45.e1 PMCID:PMC4100777

[64] Chayanupatkul M,Mittal S.Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.J Hepatol2017;66:355-62

[65] Hsu IC,Sun T,Wang NJ.Mutational hotspot in the p53 gene in human hepatocellular carcinomas.Nature1991;350:427-8

[66] AFEF. 2020. Available from: https://afef.asso.fr/wp-content/uploads/2020/07/DNI-VERSION-FINALE-RECO-2020.pdf. [Last accessed on 17 Mar 2021]

[67] Wong VW.Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?.J Hepatol2015;63:722-32

[68] Trinchet JC,Bourcier V.Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH)Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities.Hepatology2011;54:1987-97

[69] Costentin CE,Bourcier V.ANRS CO12 CirVir GroupCompliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: A Multi-Center Cohort Study.Gastroenterology2018;155:431-42.e10

[70] WHO. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. [Last accessed on 17 Mar 2021]

[71] Yang JD,Aziz AO.Africa Network for Gastrointestinal and Liver DiseasesCharacteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium.Lancet Gastroenterol Hepatol2017;2:103-111

[72] Ayoub HH,Kouyoumjian SP.Characterizing the historical role of parenteral antischistosomal therapy in hepatitis C virus transmission in Egypt.Int J Epidemiol2020;49:798-809 PMCID:PMC7394952

[73] Okeke E,Roberts L.Epidemiology of Liver Cancer in Africa: Current and Future Trends.Semin Liver Dis2020;40:111-23

[74] Kew MC.Hepatic iron overload and hepatocellular carcinoma.Liver Cancer2014;3:31-40 PMCID:PMC3995380

[75] Yang JD,Afihene MY.Africa Network for Gastrointestinal and Liver DiseasesHepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic hepatitis B.Am J Gastroenterol2015;110:1629-31

[76] Sultan A,Wondifraw Z,Bane A.Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa.Expert Rev Gastroenterol Hepatol2020;14:1007-11 PMCID:PMC7544626

[77] Aby ES,Sultan A,Debes JD.Outcomes of sorafenib therapy in advanced hepatocellular carcinoma in a single center in Ethiopia.Eur J Gastroenterol Hepatol2020;32:1407-8

[78] Breakwell L,Childs L,Tohme R.The status of hepatitis B control in the African region.Pan Afr Med J2017;27:17 PMCID:PMC5745934

[79] Spearman CW.Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine.S Afr Med J2014;104:610-2

[80] Wilson P,Jhaveri R.Call to action: Prevention of mother-to-child transmission of hepatitis B in Africa.J Infect Dis2018;217:1180-3 PMCID:PMC6279162

[81] Dooso Oloo R,Wachira P.Genetic Profiling of Aspergillus Isolates with Varying Aflatoxin Production Potential from Different Maize-Growing Regions of Kenya.Toxins (Basel)2019;11:467 PMCID:PMC6723045

[82] Szymańska K,Kirk GD.Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa.Int J Cancer2004;110:374-9

[83] Ryder RW,Sanneh AB,Tulloch S.Persistent hepatitis B virus infection and hepatoma in The Gambia, west Africa. A case-control study of 140 adults and their 603 family contacts.Am J Epidemiol1992;136:1122-31

[84] Wills W,Brochard C.Hepatitis B surface antigen (Australia antigen) in mosquitoes collected in Senegal, West Africa.Am J Trop Med Hyg1976;25:186-90

[85] Maponga TG,Glashoff RH.Hepatitis B virus-associated hepatocellular carcinoma in South Africa in the era of HIV.BMC Gastroenterol2020;20:226 PMCID:PMC7359588

[86] Lemoine M.Battlefield against hepatitis B infection and HCC in Africa.J Hepatol2017;66:645-54

[87] Stewart KA,Navarro SM.Trends in ultrasound use in low and middle income countries: A systematic review.Int J MCH AIDS2020;9:103-20 PMCID:PMC7031872

[88] Shah S,Hanif M.Increased burden of disease and role of health economics: Asia-pacific region.Expert Rev Pharmacoecon Outcomes Res2019;19:517-28

[89] Wong TW.A review of statutory medical examinations in Asian-Pacific countries.Am J Ind Med2011;54:78-88

[90] Ashtari S,Sharifian A.Hepatocellular carcinoma in Asia: Prevention strategy and planning.World J Hepatol2015;7:1708-17 PMCID:PMC4483553

[91] Bertuccio P,Turati F.Global trends and predictions in hepatocellular carcinoma mortality.J Hepatol2017;67:302-9

[92] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[93] Liaw YF.Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia.J Hepatol2009;51:403-10

[94] Liu Y.Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.Environ Health Perspect2010;118:818-24 PMCID:PMC2898859

[95] Jafri W.Hepatocellular carcinoma in Asia: A challenging situation.Euroasian J Hepatogastroenterol2019;9:27-33 PMCID:PMC6969322

[96] Kar P.Risk factors for hepatocellular carcinoma in India.J Clin Exp Hepatol2014;4:S34-42 PMCID:PMC4284237

[97] Raihan R,Al Mahtab M.Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh.PLoS One2019;14:e0218744 PMCID:PMC6599139

[98] Chuon C,Matsuo J.High possibility of hepatocarcinogenesis in HBV genotype C1 infected Cambodians is indicated by 340 HBV C1 full-genomes analysis from GenBank.Sci Rep2019;9:12186 PMCID:PMC6704254

[99] Sarin SK,Lau GK.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatol Int2016;10:1-98 PMCID:PMC4722087

[100] Howell J,Cowie BC.Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030.J Gastroenterol Hepatol2019;34:40-8

[101] Blumberg BS,Visnich S.A "NEW" ANTIGEN IN LEUKEMIA SERA.JAMA1965;191:541-6

[102] MacLachlan J,Carville K,Cowie B.Mapping progress in chronic hepatitis B: geographic variation in prevalence, diagnosis, monitoring and treatment, 2013-15.Aust N Z J Public Health2018;42:62-8

[103] Hong TP,Fink M.Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed.Hepatology2016;63:1205-12

[104] Mules T,Lithgow O,McCall J.Hepatitis B virus-related hepatocellular carcinoma presenting at an advanced stage: is it preventable?.N Z Med J2018;131:27-35

[105] Jackson K,Holgate .Hepatitis B and D in the Pacific Islands of Kiribati.J Clin Virol2020;129:104527

[106] MacLachlan JH.Liver cancer is the fastest increasing cause of cancer death in Australians.Med J Aus2012;19:492-3

[107] Lubel JS,Strasser SI.Australian recommendations for the management of hepatocellular carcinoma: a consensus statement.Med J Aust2020;